Pd-1 is a novel regulator of human B-cell activation

International Immunology

Volumn 25, Issue 2, 2013, Pages 129-137

  Thibult, Marie Laure ^a,b,c,d,e   Mamessier, Emilie ^a,b,c,d,e   Gertner dardenne, Julie ^a,b,c,d   Pastor, Sonia ^a,b,c,d   Just landi, Sylvaine ^a,b,c,d   Xerri, Luc ^a,b,c,d   Chetaille, Bruno ^a,b,c,d   Olive, Daniel ^a,b,c,d  

^a AIX MARSEILLE UNIVERSITY   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d CNRS   (France)

^e CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

Author keywords

B cells; Co signalization; CpG; PD 1

Indexed keywords

IMMUNOGLOBULIN M; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PROGRAMMED DEATH 1 LIGAND 1; TOLL LIKE RECEPTOR 9;

ARTICLE; B LYMPHOCYTE ACTIVATION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GERMINAL CENTER; HUMAN; HUMAN CELL; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MEMORY CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

B-LYMPHOCYTES; HUMANS; LYMPHOCYTE ACTIVATION; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84873821509     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxs098     Document Type: Article

References (44)

1. Ishida, Y., Agata, Y., Shibahara, K. and Honjo, T. 1992. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887.
2. Watanabe, N., Gavrieli, M., Sedy, J. R. et al. 2003. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 4:670.
3. Greenwald, R. J., Freeman, G. J. and Sharpe, A. H. 2005. The B7 family revisited. Annu. Rev. Immunol. 23:515.
4. Nishimura, H., Minato, N., Nakano, T. and Honjo, T. 1998. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 10:1563.
5. Blank, C., Brown, I., Marks, R., Nishimura, H., Honjo, T. and Gajewski, T. F. 2003. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J. Immunol. 171:4574.
6. Waterhouse, P., Penninger, J. M., Timms, E. et al. 1995. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270:985.
7. Gavrieli, M., Watanabe, N., Loftin, S. K., Murphy, T. L. and Murphy, K. M. 2003. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem. Biophys. Res. Commun. 312:1236.
8. Agata, Y., Kawasaki, A., Nishimura, H. et al. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol. 8:765.
9. Ansari, M. J., Salama, A. D., Chitnis, T. et al. 2003. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J. Exp. Med. 198:63.
10. Gonzalez, L. C., Loyet, K. M., Calemine-Fenaux, J. et al. 2005. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc. Natl. Acad. Sci. U.S.A. 102:1116.
11. Dong, H., Zhu, G., Tamada, K. and Chen, L. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5:1365.
12. Freeman, G. J., Long, A. J., Iwai, Y. et al. 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:1027.
13. Tseng, S. Y., Otsuji, M., Gorski, K. et al. 2001. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J. Exp. Med. 193:839.
14. Latchman, Y., Wood, C. R., Chernova, T. et al. 2001. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2:261.
15. Ghiotto, M., Gauthier, L., Serriari, N. et al. 2010. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int. Immunol. 22:651.
16. Kaku, H. and Rothstein, T. L. 2010. Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells through lineage-specific activity of a unique, intronic promoter. Genes Immun. 11:55.
17. Messal, N., Serriari, N. E., Pastor, S., Nunès, J. A. and Olive, D. 2011. PD-L2 is expressed on activated human T cells and regulates their function. Mol. Immunol. 48:2214.
18. Yamazaki, T., Akiba, H., Iwai, H. et al. 2002. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169:5538.
19. Zhang, J. Y., Zhang, Z., Wang, X. et al. 2007. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 109:4671.
20. Zhang, L., Gajewski, T. F. and Kline, J. 2009. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 114:1545.
21. Rosenwald, A., Wright, G., Leroy, K. et al. 2003. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198:851.
22. Dorfman, D. M., Brown, J. A., Shahsafaei, A. and Freeman, G. J. 2006. Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am. J. Surg. Pathol. 30:802.
23. Hamanishi, J., Mandai, M., Iwasaki, M. et al. 2007. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 104:3360.
24. Strome, S. E., Dong, H., Tamura, H. et al. 2003. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63:6501.
25. Curiel, T. J., Wei, S., Dong, H. et al. 2003. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9:562.
26. Ohigashi, Y., Sho, M., Yamada, Y. et al. 2005. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res. 11:2947.
27. Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T. and Honjo, T. 2001. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. U.S.A. 98:13866.
28. Kruetzmann, S., Rosado, M. M., Weber, H. et al. 2003. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J. Exp. Med. 197:939.
29. Carsetti, R., Rosado, M. M. and Wardmann, H. 2004. Peripheral development of B cells in mouse and man. Immunol. Rev. 197:179.
30. Weller, S., Braun, M. C., Tan, B. K. et al. 2004. Human blood IgM "memory" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 104:3647.
31. Weller, S., Faili, A., Garcia, C. et al. 2001. CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans. Proc. Natl. Acad. Sci. U.S.A. 98:1166.
32. Klein, U., Rajewsky, K. and Küppers, R. 1998. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J. Exp. Med. 188:1679.
33. Serriari, N. E., Gondois-Rey, F., Guillaume, Y. et al. 2010. B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function. J. Immunol. 185:3140.
34. Zhang, M., Howard, K., Winters, A. et al. 2011. Monoclonal antibodies to B and T lymphocyte attenuator (BTLA) have no effect on in vitro B cell proliferation and act to inhibit in vitro T cell proliferation when presented in a cis, but not trans, format relative to the activating stimulus. Clin. Exp. Immunol. 163:77.
35. Harwood, N. E. and Batista, F. D. 2011. The cytoskeleton coordinates the early events of B-cell activation. Cold Spring Harb. Perspect. Biol. 3:a002360.
36. Good-Jacobson, K. L., Szumilas, C. G., Chen, L., Sharpe, A. H., Tomayko, M. M. and Shlomchik, M. J. 2010. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat. Immunol. 11:535.
37. M'Hidi, H., Thibult, M. L., Chetaille, B. et al. 2009. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Am. J. Clin. Pathol. 132:589.
38. Vendel, A. C., Calemine-Fenaux, J., Izrael-Tomasevic, A., Chauhan, V., Arnott, D. and Eaton, D. L. 2009. B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. J. Immunol. 182:1509.
39. Freeman, G. J., Gribben, J. G., Boussiotis, V. A. et al. 1993. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909.
40. Freeman, G. J., Borriello, F., Hodes, R. J. et al. 1993. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J. Exp. Med. 178:2185.
41. Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H. and Freeman, G. J. 2007. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27:111.
42. Nathan, C. 2002. Points of control in inflammation. Nature 420:846.
43. Dotti, G. 2009. Blocking PD-1 in cancer immunotherapy. Blood 114:1457.
44. Berger, R., Rotem-Yehudar, R., Slama, G. et al. 2008. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14:3044.